关于已知抗病毒药物对抗新型冠状病毒肺炎的数据。
Data on known anti-virals in combating CoVid-19.
作者信息
Akshayaa L, Lakshmi Thangavelu, Devaraj Ezhilarasan, Roy Anitha, Raghunandhakumar S, Sivaperumal P, David Sheba, Dua Kamal, Chellappan Dinesh Kumar
机构信息
Department of Pharmacology, Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai-600077, TamilNadu.
PAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Brunei.
出版信息
Bioinformation. 2020 Nov 30;16(11):878-881. doi: 10.6026/97320630016878. eCollection 2020.
Abstract
Design and development of effective anti-virals in combating CoVid-19 is a great challenge worldwide. Known drugs such as chloroquine, lopinavir, favipiravir and remdesivir are used in the management of CoVid - 19. It is known that Ivermectin and remdesivir both are effective against filoviruses, paramyxo viruses. Available data also shows that ivermectin and remedesivir repress the replication of SARS-CoV-2. Thus, we document the potential use of ivermectin and remdesivir in the management of CoVid -19.
摘要
设计和开发有效的抗新冠病毒药物是全球面临的巨大挑战。氯喹、洛匹那韦、法匹拉韦和瑞德西韦等已知药物被用于新冠病毒的治疗。已知伊维菌素和瑞德西韦对丝状病毒、副粘病毒均有效。现有数据还表明，伊维菌素和瑞德西韦可抑制新冠病毒的复制。因此，我们记录了伊维菌素和瑞德西韦在新冠病毒治疗中的潜在用途。
相似文献
1
Data on known anti-virals in combating CoVid-19.关于已知抗病毒药物对抗新型冠状病毒肺炎的数据。
Bioinformation. 2020 Nov 30;16(11):878-881. doi: 10.6026/97320630016878. eCollection 2020.
2
Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.瑞德西韦、洛匹那韦/利托那韦和氯喹/羟氯喹影响新型 SARS-CoV-2 的抗病毒机制研究进展。
Biomed Pharmacother. 2020 Nov;131:110668. doi: 10.1016/j.biopha.2020.110668. Epub 2020 Aug 24.
3
Combination Treatment With Remdesivir and Ivermectin Exerts Highly Synergistic and Potent Antiviral Activity Against Murine Coronavirus Infection.联合使用瑞德西韦和伊维菌素对小鼠冠状病毒感染具有高度协同和强大的抗病毒活性。
Front Cell Infect Microbiol. 2021 Jul 30;11:700502. doi: 10.3389/fcimb.2021.700502. eCollection 2021.
4
Safety profile of COVID-19 drugs in a real clinical setting.在真实临床环境中 COVID-19 药物的安全性概况。
Eur J Clin Pharmacol. 2022 May;78(5):733-753. doi: 10.1007/s00228-021-03270-2. Epub 2022 Jan 28.
5
Effectiveness of Remdesivir, Lopinavir/Ritonavir, and Favipiravir for COVID-19 Treatment: A Systematic Review.瑞德西韦、洛匹那韦/利托那韦和法匹拉韦治疗新型冠状病毒肺炎的疗效：一项系统评价
Int J Gen Med. 2021 Nov 23;14:8557-8571. doi: 10.2147/IJGM.S332458. eCollection 2021.
6
Molecular Docking Reveals Ivermectin and Remdesivir as Potential Repurposed Drugs Against SARS-CoV-2.分子对接显示伊维菌素和瑞德西韦是针对新冠病毒的潜在重新利用药物。
Front Microbiol. 2021 Jan 25;11:592908. doi: 10.3389/fmicb.2020.592908. eCollection 2020.
7
Antiviral treatment of COVID-19.COVID-19 的抗病毒治疗。
Turk J Med Sci. 2020 Apr 21;50(SI-1):611-619. doi: 10.3906/sag-2004-145.
8
SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.SARS-CoV-2：洛匹那韦/利托那韦、达芦那韦/乌苯美司、羟氯喹、瑞德西韦、法匹拉韦等药物治疗新型冠状病毒的抗病毒治疗的最新报告。
Curr Med Chem. 2020;27(27):4536-4541. doi: 10.2174/0929867327666200416131117.
9
Co-administration of Favipiravir and the Remdesivir Metabolite GS-441524 Effectively Reduces SARS-CoV-2 Replication in the Lungs of the Syrian Hamster Model.法匹拉韦与瑞德西韦代谢产物 GS-441524 联合用药能有效抑制 SARS-CoV-2 在叙利亚仓鼠模型肺部的复制。
mBio. 2021 Feb 22;13(1):e0304421. doi: 10.1128/mbio.03044-21. Epub 2022 Feb 1.
10
A guide to COVID-19 antiviral therapeutics: a summary and perspective of the antiviral weapons against SARS-CoV-2 infection.《COVID-19 抗病毒治疗药物指南：抗 SARS-CoV-2 感染的抗病毒武器概述与展望》
FEBS J. 2024 Apr;291(8):1632-1662. doi: 10.1111/febs.16662. Epub 2022 Nov 5.
引用本文的文献
1
Melanin pigments from sediment-associated sp. marine actinobacterium and antibacterial potential.来自沉积物相关海洋放线菌的黑色素色素及其抗菌潜力。
J Adv Pharm Technol Res. 2022 Nov;13(Suppl 1):S88-S92. doi: 10.4103/japtr.japtr_339_22. Epub 2022 Nov 30.
本文引用的文献
1
Infection of human sweat glands by SARS-CoV-2.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染人体汗腺。
Cell Discov. 2020 Nov 13;6(1):84. doi: 10.1038/s41421-020-00229-y.
2
Compassionate Use of Remdesivir in Covid-19. Reply.瑞德西韦在新冠病毒病中的同情用药。回复。
N Engl J Med. 2020 Jun 18;382(25):e101. doi: 10.1056/NEJMc2015312. Epub 2020 May 15.
3
First Case of Covid-19 in the United States. Reply.美国首例新冠病毒病病例。回复。
N Engl J Med. 2020 May 7;382(21):e53. doi: 10.1056/NEJMc2004794. Epub 2020 Apr 22.
4
Antiviral treatment of COVID-19.COVID-19 的抗病毒治疗。
Turk J Med Sci. 2020 Apr 21;50(SI-1):611-619. doi: 10.3906/sag-2004-145.
5
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.美国食品药品监督管理局批准的药物伊维菌素可抑制 SARS-CoV-2 的体外复制。
Antiviral Res. 2020 Jun;178:104787. doi: 10.1016/j.antiviral.2020.104787. Epub 2020 Apr 3.
6
The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.2019 冠状病毒病（COVID-19）疫情的起源、传播和临床治疗——现状更新。
Mil Med Res. 2020 Mar 13;7(1):11. doi: 10.1186/s40779-020-00240-0.
7
Presumed Asymptomatic Carrier Transmission of COVID-19.新冠病毒无症状感染者的传播。
JAMA. 2020 Apr 14;323(14):1406-1407. doi: 10.1001/jama.2020.2565.
8
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.预防性和治疗性瑞德西韦（GS-5734）治疗中东呼吸综合征冠状病毒感染恒河猴模型。
Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6771-6776. doi: 10.1073/pnas.1922083117. Epub 2020 Feb 13.
9
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.瑞德西韦和氯喹在体外能有效抑制新出现的新型冠状病毒（2019 - 新冠病毒）。
Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4.
10
Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase.广谱抗病毒药物瑞德西韦通过高度分化的 RNA 依赖的 RNA 聚合酶抑制人类地方性和人畜共患的德尔塔冠状病毒。
Antiviral Res. 2019 Sep;169:104541. doi: 10.1016/j.antiviral.2019.104541. Epub 2019 Jun 21.
Zotero 插件